Investigation in Progress — No Complaint Filed Yet
BG&G is actively investigating potential securities fraud claims against Outset Medical, Inc.. If a complaint is filed, this page will be updated. Investors are encouraged to contact us now to preserve their rights.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Outset Medical, Inc. (“Outset Medical” or “the Company”) (NASDAQ: OM). Investors who purchased Outset Medical securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Outset Medical has violated federal securities laws.
Outset Medical Investigation Details
On November 10, 2025, Outset Medical issued a press release announcing the Company’s financial results for the third quarter of 2025. Among other items, Outset Medical reported non-GAAP earnings per share of -$0.69, missing consensus estimates by $0.03, and revenue of $29.43 million, missing consensus estimates by $1.27 million. The Company also revised its revenue outlook for 2025 to a range of $115 million to $120 million, down from a prior range of $122 million to $126 million, stating that “the expected timing to close several large opportunities forecasted for the second half of 2025 has shifted.” On this news, Outset Medical’s stock price fell $5.85 per share, or 48.47%, to close at $6.22 per share on November 11, 2025.
What’s Next for Outset Medical Investors?
If you are aware of any facts relating to this investigation or purchased Outset Medical securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
OM — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”